English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background:  Silent and overt ischemic brain lesions are common and associated with adverse outcome. Whether the CHA 2 DS 2 -VASc score and its components predict magnetic resonance imaging (MRI)-detected ischemic silent and overt brain lesions in patients with atrial fibrillation (AF) is unclear.   Methods:  In this cross-sectional analysis, patients with AF were enrolled in a multicenter cohort study in Switzerland. Outcomes were clinically overt, silent [in the absence of a history of stroke/transient ischemic attack (TIA)] and any MRI-detected ischemic brain lesions. Logistic regression analyses were performed to assess the relationship of the CHA 2 DS 2 -VASc score and its components with ischemic brain lesions. An adapted CHA 2 D-VASc score (excluding history of stroke/TIA) for the analyses of clinically overt and silent ischemic brain lesions was used.   Results:  Overall, 1,741 patients were included in the analysis (age 73 ± 8 years, 27.4% female). At least one ischemic brain lesion was observed in 36.8% (clinically overt: 10.5%; silent: 22.9%; transient ischemic attack: 3.4%). The CHA 2 D-VASc score was strongly associated with clinically overt and silent ischemic brain lesions {odds ratio (OR) [95% confidence interval (CI)] 1.32 (1.17–1.49),  p  < 0.001 and 1.20 (1.10–1.30),  p  < 0.001, respectively}. Age 65–74 years (OR 2.58; 95%CI 1.29–5.90;  p  = 0.013), age ≥75 years (4.13; 2.07–9.43;  p  < 0.001), hypertension (1.90; 1.28–2.88;  p  = 0.002) and diabetes (1.48; 1.00–2.18;  p  = 0.047) were associated with clinically overt brain lesions, whereas age 65–74 years (1.95; 1.26–3.10;  p  = 0.004), age ≥75 years (3.06; 1.98–4.89;  p  < 0.001) and vascular disease (1.39; 1.07–1.79;  p  = 0.012) were associated with silent ischemic brain lesions.   Conclusions:  A higher CHA 2 D-VASc score was associated with a higher risk of both overt and silent ischemic brain lesions.   Clinical Trial Registration:   www.ClinicalTrials.gov , identifier: NCT02105844.

Association of the CHA2D(S2)-VASc Score and Its Components With Overt and Silent Ischemic Brain Lesions in Patients With Atrial Fibrillation